Premium
Bencyclane as an anti‐sickling agent
Author(s) -
KOÇAK RIKKAT,
BAŞLAMIŞLI FIKRI,
GÜVENÇ BIROL,
TAMER LÜLÜFER,
AIKIMBAEV KAIRGUELDY S.,
ISBIR TURGAY
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.d01-1466.x
Subject(s) - pharmacology , chemistry , vasodilation , medicine , atpase , endocrinology , biochemistry , enzyme
A vasodilating Ca 2+ channel blocker, bencyclane, was used in 18 patients with homozygous sickle cell anaemia (SCD) to test the possible anti‐sickling effect. With bencylane intervention the Na + ‐K + ATPase activity increased from 256±29 to 331±37 nmol Pi/mg protein/h ( P <0.0001) and the Ca 2+ ‐Mg 2+ ATPase level increased from 172±12 to 222±44 nmol Pi/mg protein/h ( P <0.0001). The intracytoplasmic Ca 2+ concentration reduced from 3.5±0.6 to 2.7±0.25 μmol/l ( P <0.0001). The patient’s blood contained fewer irreversibly sickled cells (ISCs) (a reduction from 21.4% to 14.4%) ( P <0.05). At the same time MCHC of the erythrocytes decreased from 34.5 to 33.0 g/dl ( P <0.05). Bencyclane appears to be a promising anti‐sickling agent that can be used orally in SCD.